This study investigates mesothelin expressing solid cancers. The purpose of this study is to evaluate an investigational medication in patients with advanced, metastatic, or recurrent solid malignancies that express mesothelin.
The study focuses on evaluating the safety and effectiveness of the investigational medication. It will assess how well patients tolerate the treatment and determine the best dose for future studies.
- Who can participate: Adults 18 years and older with mesothelin expressing cancers can participate. Participants must have had at least one prior treatment and meet specific health criteria.
- Study details: Participants will receive the investigational medication in cycles and may also receive a placebo, an inactive substance that looks like the investigational medicine.
- Study timelines: The study will last 12 months.
How understandable was the trial content above?
Hard to understand
Easy to understand